Trospium chloride in older patients with idiopathic overactive urinary badder
https://doi.org/10.37586/2686-8636-1-2022-58-63
Abstract
Overactive bladder (OAB) — is a clinical syndrome which includes urge urination with or without urge urinary incontinence which is usually accompanied by frequent urination and nocturia. In most cases, OAB does not pose a threat to the life of patients, but significantly worsens the quality of all spheres of human life. Urge urinary incontinence is one of the main causes of falls in older patients, which often leads to fractures of the proximal femur and is accompanied by severe complications. Drug therapy with M-cholinoblockers (cholinolytics) is the leading direction in the treatment of patients with OAB. However, this type of therapy remains poorly understood in older men and women. The choice of an effective and safe cholinolytic for older and senile patients is the subject of discussion and scientific research. The results obtained show trospium chloride as an effective drug for the treatment of urgent and frequent urination due to idiopathic OAB, as well as the lack of influence on cognitive function in older patients.
About the Authors
G. G. Krivoborodov
Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University, Department of Urology and Andrology, Faculty of General Medicine
Russian Federation
Russian Federation
MD, PhD, professor of Urology and Andrology Department, Faculty of General Medicine; Head of Urology Department
Moscow
O. N. Tkacheva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
MD, PhD, professor, Director, Russian Gerontology Research and Clinical Centre
+7(499)187-64-67
Moscow
N. S. Efremov
Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University, Department of Urology and Andrology, Faculty of General Medicine
Russian Federation
Russian Federation
MD, PhD, Assistant professor of Urology and Andrology Department, Faculty of General Medicine
Moscow
D. A. Shyrin
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
MD, Junior Research Fellow of Geriatrics Laboratory
Moscow
A. A. Gontar
Pirogov Russian National Research Medical University, Department of Urology and Andrology, Faculty of General Medicine
Russian Federation
Russian Federation
Moscow
References
1. Irwin D.E., Kopp Z.S., Agatep B. et al World-wide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011 Oct; 108 (7): 1132–8. DOI: 10.1111/j.1464-410X.2010.09993.x.
2. Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study // BJU Int. — 2001; 87: 760–6. DOI: 10.1046/j.1464-410x.2001.02228.x.
3. Stewart W.F., Van Rooyen J.B., Cundiff G.W. et al. Prevalence and burden of overactive bladder in the United States. World J Urol. — 2003; 20: 327–36. DOI: 10.1007/s00345-002-0301-4.
4. Irwin D.E., Abrams P., Milsom I. et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. — 2008; 101(11): 1381–7.
5. https://rosinfostat.ru/prodolzhitelnost-zhizni
6. Nakagawa H., Kaijun Niu, Atsushi Hozawa et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol. — 2010; 184: 1413–1418. DOI: 10.1016/j.juro.2010.05.093.
7. Karin S. Coyne, Chris C. Sexton, Christine L. Thompson et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009 Aug; 104(3): 352–60. DOI: 10.1111/j.1464-410X.2009.08427.x.
8. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006; 47 Suppl 2(Suppl 2): S80–S87. DOI: 10.1038/sj.bjp.0706560.
9. F.C. Burkhard (Chair), J.L.H.R. Bosch, F. Cruz, G.E. Lemack, et al. Urinary incontinence in adults. EAU guidelines 2020.
10. Scheife R., Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005; 27(2): 144–153. DOI: 10.1016/j.clinthera.2005.02.014.
11. Chancellor M.B., Staskin D.R., Kay G.G., et al. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1; 29(4): 259–73. DOI: 10.2165/11597530-000000000-00000.
12. Scheife R., Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005; 27(2): 144–153. DOI: 10.1016/j.clinthera.2005.02.014.
13. Kerdraon J., Robain G., Jeandel C., et al. Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly. Prog Urol. 2014; 24(11): 672–681. DOI: 10.1016/j.purol.2014.06.003.
14. Staskin D.R. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005; 22(12): 1013–1028. DOI: 10.2165/00002512-200522120-00003.
15. Yang Y.-W., Liu H.-H., Lin T.-H., et al. Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. April 6, 2017. PLoS ONE 12(4): e0175335. https://doi.org/10.1371/journal. pone.0175335
16. H. van de Waterbeemd, G. Gamenisch, G. Folkers et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6(2): 151–65. DOI: 10.3109/10611869808997889.
17. T.M. Kessler, Lucas M. Bachmann, Christoph Minder et al. Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach. PLoS One 2011 Feb 23; 6(2): e16718. DOI: 10.1371/journal.pone.0016718.
18. Araklitis G., Robinson D., Cardozo L. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder. Clin Interv Aging. 2020; 15: 1493–1503. DOI: 10.2147/CIA.S252852.
19. Biastre K., Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009; 43(2): 283–295. DOI: 10.1345/aph.1L160.
20. McFerren S.C., Gomelsky A. Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. Drugs Aging. 2015; 32(10): 809–819. DOI: 10.1007/s40266-015-0301-x.
21. Chancellor M., Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012 Feb; 18(2): 167–74. DOI: 10.1111/j.1755-5949.2011.00248.x.
22. Doroshyenko O., Jetter A., Odenthal K.P., Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005; 44(7): 701–20. Review. DOI: 10.2165/00003088-200544070-00003.
23. Biastre K., Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009 Feb; 43(2): 283–95. DOI: 10.1345/aph.1L160.
24. Krivoborodov G.G., Tur E.I., Efremov N.S., Shkolnikov M.E. High doses of trospium chloride in patients with overactive bladder due to neuro- logic disease. The multicenter observational program RESOURCE. Consilium Medicum. 2015; 17 (12): 64–67.
25. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2.
26. https://cr.minzdrav.gov.ru/recomend/8_1
Review
For citations:
Krivoborodov G.G., Tkacheva O.N., Efremov N.S., Shyrin D.A., Gontar A.A. Trospium chloride in older patients with idiopathic overactive urinary badder. Russian Journal of Geriatric Medicine. 2022;(1):58-63. (In Russ.) https://doi.org/10.37586/2686-8636-1-2022-58-63
Views:
452
Email this article 